Puyuanhewei

PreclinicalSmall molecule

SShandong University

Puyuanhewei is one of 18 small molecule programs targeting Dyspepsia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

DyspepsiaActive, not recruiting

DyspepsiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

23 competitors in Dyspepsia

#DrugCompanyPhaseTrials

Prevacid

Takeda

Approved

3 2

Buspar

Bristol-Myers Squibb

Approved

1 3

Nexium

DDexcel Pharma Technologies Ltd.

Approved

6 4

Protonix

WWyeth-Lederle Vaccines

Approved

5 5

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

4 6

Resotran

Pepcid

2 8

Osmitrol

BB. Braun Medical Inc.

Approved

1 9

Pulmicort

SSalix

Approved

1 10

Itopride Hydrochloride

FForest Laboratories

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Dyspepsia1 trial

Gastric Barrier Dysfunction of Functional Dyspepsia and Therapeutic Response to Puyuanhewei Detected by Endomicroscopy

Unknown status·SShandong University·N/A·NCT02465996·200 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Puyuanhewei. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Puyuanhewei compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Puyuanhewei. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shandong University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShandong University

Puyuanhewei

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Dyspepsia1 trial

References

Drug Info

Quick Facts

Related News